CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-403

Thanks for your message. Looking forward to discussing the stock with whoever.

After a rigorous analysis, which includes an exhaustive review of both fundamental and technical factors, along with a close examination of investor sentiment and discussions with industry insiders, it has become alarmingly clear that EYE is significantly overvalued. The current trading price far exceeds its true worth, and I foresee a sharp correction on the horizon, with the stock likely head towards its fair value range of $0.175 to $0.19.